August 15th 2024
Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.
August 8th 2024
Shannon Westin, MD, MPH, FACOG, discusses the FDA approval of durvalumab plus chemotherapy in dMMR advanced or recurrent endometrial cancer.
April 11th 2024
Shannon N. Westin, MD, MPH, FACOG, discusses the DENALI trial of azenosertib in patients with high-grade serous ovarian cancer.
August 10th 2023
The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.
An overview of ongoing research in the endometrial cancer treatment space.
August 3rd 2023
The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.
A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.
July 27th 2023
Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.
The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.
July 20th 2023
Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.
A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.
July 13th 2023
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.
July 6th 2023
A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.
An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.
June 29th 2023
Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.
A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.
November 17th 2022
The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.
Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.
November 10th 2022
A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.